Hepatitis C treatment

Hepatitis C treatment features

• 

  Full speed ahead to curing hepatitis C

  New drugs that directly target the hepatitis C virus usher in a new era of treatment, Liz Highleyman reports. ...

  From:  HIV treatment update

• 

  We’re getting there: towards a comprehensive hepatitis C cure

  Research on new cures for hepatitis C has made rapid progress, Gus Cairns reports....

  From:  HIV treatment update

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:  HIV treatment update

• 

  The new epidemic: HIV and hepatitis C infection in gay men

  “I’m surprised there isn’t a greater sense of urgency about this in the community.” Those were the words of Dr Kevin Fenton of the US Centers for...

  From:  HIV treatment update

• 

  Management of HIV and hepatitis B or C co-infection in resource-limited settings

  Review of management of HIV and hepatitis co-infection with particular focus on antiretroviral therapy and liver disease in resource-limited settings....

  From:  HIV & AIDS treatment in practice

Hepatitis C treatment in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From:In your own words

Hepatitis C treatment news from aidsmap

• French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

  Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.The advent of ...

  05 March 2013 | Liz Highleyman

• Sofosbuvir/ledipasvir/ribavirin cures 100% of genotype 1 hepatitis C patients

  An interferon-free regimen containing sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders, according to data presented yesterday at the ...

  05 March 2013 | Liz Highleyman

• Study shows value of hepatitis C therapy for HIV co-infected patients with compensated cirrhosis

  Spanish research published in the online edition of Clinical Infectious Diseases shows the benefits of successful hepatitis C therapy for people co-infected with HIV who have compensated liver cirrhosis. Achievement of a sustained virological response (SVR) was associated with lower ...

  28 February 2013 | Michael Carter

• Support improves hepatitis C treatment completion and response rates among drug users

  Hepatitis C treatment completion and response rates among injecting drug users are similar to those seen in general patient populations, the findings of a meta-analysis published in the online edition of Clinical Infectious Diseases show. The best outcomes were seen ...

  02 January 2013 | Michael Carter

• Adherence to hepatitis C treatment: unravelling the complexities

  Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting 2012, the 63rd annual meeting of the ...

  13 December 2012 | Rob Camp

• Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis

  The hepatitis C protease inhibitor telaprevir (Incivo or Incivek) taken twice daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved three-times-daily schedule, with similar safety and tolerability even for people with ...

  23 November 2012 | Liz Highleyman

• Which patients should be prioritised for new hepatitis C treatments?

  Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to a modelling exercise presented by University of ...

  23 November 2012 | Rob Camp

• Low viral load in hepatitis C treatment: Is a third drug necessary?

  When resources for hepatitis C treatment with new directly acting antivirals are limited, findings from the United States suggest that previously untreated people with low viral loads may stand a good chance of achieving a sustained virologic response without ...

  23 November 2012 | Rob Camp

• Antiviral treatment reduces risk of liver cancer in people with hepatitis C-related cirrhosis and fibrosis

  Antiviral treatment reduces the risk of hepatocellular carcinoma (HCC) in people with hepatitis C-related fibrosis or cirrhosis, according to the results of a meta-analysis published in British Medical Journal Open. The risk was reduced irrespective of the virological outcome ...

  29 October 2012 | Michael Carter

• Vitamin D deficiency associated with a poorer response to HCV treatment in HIV/HCV-co-infected patients

  Vitamin D deficiency is associated with a poorer response to hepatitis C therapy in people who are co-infected with HIV and hepatitis C, investigators report in the online edition of AIDS. Austrian researchers found that people with vitamin D ...

  11 October 2012 | Michael Carter

More news

Hepatitis C treatment news selected from other sources

• Roche’s Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older

  Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus.

  19 March 2013 | Roche press release

• Telaprevir shows promise in black patients with genotype 1 HCV

  Preliminary data presented here at the 2013 Conference on Retroviruses and Opportunistic Infections show that combination telaprevir treatment may be effective in black null responder patients with chronic genotype 1 hepatitis C.

  12 March 2013 | Healio

• Patient Dilemma: Treat Hepatitis C Now or Hold Out?

  Being diagnosed with a potentially fatal disease usually triggers immediate treatment. But a growing number of people infected with hepatitis C are putting off therapy, choosing instead to roll the dice and wait for a new generation of drugs to become available.

  05 March 2013 | Wall Street Journal

• Milk Thistle Drug May Help Control HCV Replication after Liver Transplant

  Silibinin, a medication derived from the milk thistle plant, lowered hepatitis C virus (HCV) levels in patients awaiting liver transplantation in a pilot study, which may help reduce the risk of HCV recurrence in the new liver, Spanish researchers reported in the March 2013 Journal of Hepatology.

  02 March 2013 | HIVandhepatitis.com

• Health Canada Warns Of Serious Skin Reactions From Hepatitis C Drug

  Two months after the FDA issued a safety alert informing about the serious skin reactions, some fatal, in patients taking Vertex Pharmaceuticals Inc.'s (VRTX: Quote) hepatitis C drug Incivek (telaprevir), it is now health Canada's turn to alert health-care providers and patients.

  01 March 2013 | RTT News

• Pakistan: Low cost Hepatitis C treatment: ‘Everything is heading in the right direction – on paper’

  The production of a local biosimilar version of interferon alfa is being delayed by bureaucratic obstacles, according to its developer.

  28 February 2013 | Express Tribune

• Pakistan: Hepatitis C patients get the axe as hospitals stop treatment

  ISLAMABAD: Most public hospitals in twin cities have stopped providing treatment to Hepatitis patients who cannot afford to pay, putting their lives at stake.

  28 February 2013 | The Express Tribune

• Hepatitis C Model Delivers Great Care Anywhere

  Optimal HCV treatment for patients in a comprehensive health system requires an efficient and effective process. Ideally, the established structure would support rural as well as urban settings and allow for sharing of information, education of providers, and metrics to monitor treatments. Such a process was established successfully within the Department of VA.

  25 February 2013 | Infectious Disease Special Edition

• Republic of Georgia plagued by hepatitis C

  Official statistics place the number of those infected with the illness at 200,000, which is approximately 6.7 percent of Georgia’s population.

  20 February 2013 | Vaccine News Daily

• Scotland: Project launched to tackle spread of Hepatitis C

  It is hoped that by giving early treatment to small numbers of people who inject drugs and are infected with hepatitis C, it will prevent the need to treat larger numbers later, reducing the risk of addicts suffering from liver cirrhosis and cancer which can develop over time if hepatitis C remains untreated.

  20 February 2013 | The Scotsman

More news